Conclusion. Ceftobiprole is a novel, broad-spectrum, parenteral cephalosporin undergoing Phase III clinical trials. Its broad spectrum of activity makes it a candidate for monotherapy of cSSSIs ...

Ceftobiprole has been approved for use in Canada. According to the Canadian prescribing information, the recommended dosage is 500 mg every 12 hours infused over 1 hour for the treatment of cSSSIs ...

The outdated advice to prescribe broad-spectrum antibiotics instead of penicillin or cephalosporins led to suboptimal treatment, higher healthcare costs, and increased rates of antibiotic resistance.